NASDAQ$RGEN

Repligen Corp · Q3 2023 earnings

Q3 2023 earnings · · Investor relations

Briefing

Repligen's third quarter results reflected resilience amidst industry challenges, marked by strengthened orders and strategic acquisitions.

Repligen reported a decrease in total revenue to $141.2 million compared to $200.7 million in Q3 2022. The company saw positive signs of recovery with a book-to-bill ratio of 1.07. They narrowed their full year revenue guidance to $635-$645 million.

  • Total third quarter revenues were reported at $141.2 million, with base business revenues of $140.1 million.
  • The company's order book strengthened, achieving a total book-to-bill ratio of 1.07.
  • Repligen acquired Metenova AB on October 2, expanding their Fluid Management offering.
  • Full year revenue guidance was narrowed to a range of $635-$645 million.

Headline financials

Total Revenue

$141M

Previous: $201M-29.7%
EPS (adj)

$0.23

Previous: $0.77-70.1%
Gross Margin

25.9%

Previous: 56.9%-54.5%
Capital Expenditures

-$25.1M

Previous: -$64.4M+61.0%
Free Cash Flow

-$6.96M

Previous: -$24M+71.0%
Net Income

$18.2M

Previous: $40.4M-55.0%
Operating Income

$4.81M

Previous: $52.7M-90.9%
Gross Profit

$36.6M

Previous: $114M-68.0%
Cash & Equivalents

$631M

Previous: $573M+10.0%
Total Assets

$2.51B

Previous: $2.46B+2.1%
R&D Expense

$10.5M

No prior period
Stock-Based Comp

$6.37M

Previous: $6.15M+3.6%

Revenue & EPS history

Repligen · Revenue · Quarterly

$141M

Q3 2023-29.7%vs Q3 2022
Beat estimate in 10 of 15 quarters(67%)
ActualEstimate

Revenue by segment

Repligen · $141M total across 2 segments · Q3 2023

  • Product Revenue
    $141M
  • Royalty and Other
    $36

Forward guidance

Repligen narrowed its full year 2023 revenue guidance to a range of $635M-$645M. The guidance includes the impact of FlexBiosys and Metenova acquisitions and excludes the impact of potential additional acquisitions, and future fluctuations in foreign currency exchange rates.

Tailwinds

  • Revenue guidance maintained at $635M-$645M.
  • Base business revenue expected to decline by 8.5%-9.5%.
  • Gross margin projected at 45.5%-46.5%.
  • Operating margin anticipated to be 10%-11%.
  • Net income forecasted at $72M-$75M.

Headwinds

  • Year-over-year change in revenue expected to be (19.5%)-(21%).
  • COVID-Related Revenue estimated at $30M.
  • Income from Operations projected at $61M-$65M.
  • Tax Rate on Pre-Tax Income estimated at 12%.
  • Earnings Per Share - Diluted projected at $1.26-$1.32.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2023

Historical avgQ3 2023

+2.6%

Avg return

Earnings day

+3.4%

Avg return

5 days after

+4.4%

Avg return

30 days after

59%

36 / 61 earnings

Positive

+22.1%

Q3 2018

Best reaction

-23.0%

Q3 2015

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.1%-7.8%-2.7%
Q4 2025+1.4%-4.9%-15.5%
Q3 2025-5.9%-7.5%+6.3%
Q1 2025-2.9%-1.5%-14.8%
Q4 2024+7.9%+7.1%-7.1%
Q3 2024+7.9%-10.6%+11.8%
Q2 2024+21.3%+17.2%+9.2%
Q1 2024+1.3%+2.3%-9.2%
Q4 2023-3.2%-4.0%-0.9%
Q3 2023+15.1%+31.7%+37.7%
Q2 2023+1.1%+2.5%+5.2%
Q1 2023+6.4%+4.3%+8.8%
Q4 2022+3.2%-2.7%-10.0%
Q3 2022-6.0%-4.5%+3.1%
Q2 2022+13.1%+15.9%+0.6%
Q1 2022+7.8%+11.4%+19.3%
Q4 2021-1.8%-1.4%+4.0%
Q3 2021+7.2%+11.7%+5.5%
Q2 2021+14.2%+19.3%+32.4%
Q1 2021-6.4%-9.8%-15.6%
Q4 2020+0.3%+7.4%-11.1%
Q3 2020+8.1%+0.0%+0.8%
Q2 2020+8.7%+12.8%+8.2%
Q1 2020+6.7%+11.9%+5.0%
Q4 2019-10.1%-22.2%-18.7%
Q3 2019+9.9%+6.1%+15.1%
Q2 2019-4.0%-3.2%-1.7%
Q1 2019+2.5%-0.2%+11.5%
Q4 2018-0.2%+1.0%-0.2%
Q3 2018+22.1%+25.2%+19.3%
Q2 2018-1.0%+2.0%+14.2%
Q1 2018+5.1%+10.2%+14.9%
Q4 2017+9.2%+9.5%+6.2%
Q3 2017-7.1%-13.0%-4.9%
Q2 2017+1.3%+4.4%+6.1%
Q1 2017+5.2%+6.3%+11.7%
Q4 2016+6.3%+6.4%+13.6%
Q3 2016-4.1%-1.1%+10.0%
Q2 2016-0.6%-1.1%+3.9%
Q1 2016+2.1%
Q4 2015+2.4%
Q3 2015-23.0%
Q2 2015-0.2%
Q1 2015+16.9%
Q4 2014+14.9%
Q3 2014-6.6%
Q2 2014-3.6%
Q1 2014+5.0%
Q4 2013-8.8%
Q3 2013+8.8%
Q2 2013-0.1%
Q1 2013+2.9%
Q3 2010-5.0%
Q4 2012+5.8%
Q3 2012+10.2%
Q2 2012-0.4%
Q4 2010-1.5%
Q1 2012+0.9%
Q2 2011-0.1%
Q1 2011-0.9%
Q4 2011-0.9%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro